We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Takeda Gets Complete Response for Alogliptin, Actos Combination
Takeda Gets Complete Response for Alogliptin, Actos Combination
September 11, 2009
The FDA has asked Takeda Pharmaceutical in a complete response letter to conduct an additional cardiovascular safety study on its proposed fixed-dose combination of alogliptin and Actos to treat Type 2 diabetes.